PMID- 35573995
OWN - NLM
STAT- MEDLINE
DCOM- 20220519
LR  - 20221207
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With 
      Type 2 Diabetes Treated With IdegLira in a Real-World Setting.
PG  - 828607
LID - 10.3389/fendo.2022.828607 [doi]
LID - 828607
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic, highly prevalent 
      disease with a significant impact on health. Appropriate treatment requires 
      effective and timely escalation to achieve metabolic control. To evaluate the 
      effectiveness and safety of IDegLira on adults with T2DM previously treated with 
      oral antidiabetics and/or insulin in a real-life setting. METHODS: An 
      observational study in a real-world setting was conducted. Patients were selected 
      from the outpatient clinic of two centers dedicated to specialized diabetes care. 
      Main outcomes were HbA1c, body weight, insulin dose changes, hypoglycemia, and 
      other adverse events. RESULTS: 67 T2DM patients treated with IDegLira were 
      monitored between 3 and 7 months. At the end of foll ow-up, the median change in 
      HbA1c was -1.05% (CI95% -1.45, -0.65), and a decrease in insulin requirement was 
      also observed (mean difference -10 TDD units (CI95% - 17 to -2.5). No treatment 
      discontinuation was reported, hypoglycemia events were reported in 3 patients at 
      the end of follow-up versus 8 patients at baseline. CONCLUSIONS: This real-life 
      study shows the effectiveness in glycemic control of IDegLira use in T2DM 
      patients who do not achieve goals with other therapies, with an adequate safety 
      profile. The findings need to be confirmed with evaluation of therapeutic results 
      in larger cohorts.
CI  - Copyright (c) 2022 Ramirez-Rincon, Builes-Montano, Hincapie-Garcia, Blanco and 
      Botero-Arango.
FAU - Ramirez-Rincon, Alex
AU  - Ramirez-Rincon A
AD  - School of Medicine, Universidad Pontificia Bolivariana, Medellin, Colombia.
AD  - Endocrinology Department, Clinica Integral de Diabetes, Medellin, Colombia.
FAU - Builes-Montano, Carlos E
AU  - Builes-Montano CE
AD  - School of Medicine, Universidad de Antioquia, Medellin, Colombia.
AD  - Endocrinology Department, Hospital Pablo Tobon Uribe, Medellin, Colombia.
FAU - Hincapie-Garcia, Jaime A
AU  - Hincapie-Garcia JA
AD  - Clinical Pharmacology, Pharmaceutical Promotion and Prevention Group, Faculty of 
      Pharmaceutical and Food Sciences, Universidad de Antioquia, Medellin, Colombia.
FAU - Blanco, Victor M
AU  - Blanco VM
AD  - School Medicine, Pontificia Universidad Bolivariana, Medellin, Colombia.
FAU - Botero-Arango, Jose F
AU  - Botero-Arango JF
AD  - School of Medicine, Universidad Pontificia Bolivariana, Medellin, Colombia.
AD  - Endocrinology Department, Clinica Integral de Diabetes, Medellin, Colombia.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220428
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Blood Glucose)
RN  - 0 (Drug Combinations)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (IDegLira)
RN  - 0 (Insulin)
RN  - 0 (Insulin, Long-Acting)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Adult
MH  - Blood Glucose/metabolism
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Drug Combinations
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - *Hypoglycemia/chemically induced/prevention & control
MH  - Insulin/therapeutic use
MH  - Insulin, Long-Acting
MH  - Liraglutide
PMC - PMC9097264
OTO - NOTNLM
OT  - IDegLira
OT  - insulin degludec
OT  - liraglutide
OT  - real-world evidence (RWE)
OT  - type 2 diabetes
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/17 06:00
MHDA- 2022/05/20 06:00
PMCR- 2022/01/01
CRDT- 2022/05/16 04:36
PHST- 2021/12/03 00:00 [received]
PHST- 2022/03/29 00:00 [accepted]
PHST- 2022/05/16 04:36 [entrez]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/05/20 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.828607 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Apr 28;13:828607. doi: 
      10.3389/fendo.2022.828607. eCollection 2022.